1 Like
Tidied transcript via chatGPT
Tidy transcript (timestamps and filler removed, lightly formatted for easy reading)
We ask a lot of questions about our diet. What’s the right way to treat a chronic illness? Fight off a virus, lose weight? The problem is, we get a lot of different answers. Well, I’m here to help—welcome to the Nutrition Facts Podcast. I’m your host, Dr Michael Greger.
It sounds like science fiction: bacteria in a vial of dirt taken from a mysterious island create a compound that prolongs life—and not just in the traditional medical sense. Thanks to advances in modern medicine, we’re living longer lives, but mostly by lengthening the morbidity phase—we’re living longer but sicker lives. Traditional medical approaches tend just to increase the number of old people in bad health. Ideally, we’d extend lifespan by slowing aging so we delay the onset of deterioration instead of merely extending the period of deterioration.
That’s exactly what this new compound—rapamycin—appeared to do. Named for its birthplace, the mystical Easter Island (Rapa Nui), rapamycin inhibits an enzyme now known as mTOR (“mechanistic target of rapamycin”), a master determinant of lifespan and aging. mTOR is the major regulator of growth in animals: it drives increases in cell size and number. But its action has been likened to the engine of a speeding car with no brakes. Aging becomes a car hurtling into the low-speed zone of adulthood, damaging itself because it can’t slow down.
Why don’t organisms have brakes? In the wild, few animals live long enough to experience aging; most die before adulthood. Throughout most of human history the same was true—17th-century Londoners rarely made it to 16. Evolution therefore selects for rapid growth and early reproduction; once genes are passed on, the growth engine (mTOR) keeps roaring even though it’s now harmful. In childhood, mTOR is an engine of growth; in adulthood, it becomes an engine of aging—an example of antagonistic pleiotropy, where a gene helpful when we’re young becomes harmful when we’re old.
Unconstrained mTOR-fueled growth has downsides: it revs up construction pathways that can feed cancerous tumors and, to keep building, actively suppresses autophagy—the cell’s own renovation and cleansing program—accelerating aging. Conversely, putting the brakes on mTOR decelerates aging; inhibiting mTOR is one of the best-validated longevity interventions we have.
Rapamycin illustrates this. Soil bacteria on Easter Island didn’t evolve the drug to help us; they made it to slow competing soil fungi. Yet dozens of studies show rapamycin extends average and maximum lifespan in mice and every other organism tested so far—even when started in mid-life. In the landmark 2009 National Institute on Aging study, 600-day-old mice (roughly 60-year-old humans) still lived ~12 % longer after starting rapamycin.
Is it “just” an anticancer effect? mTOR signaling is hyperactive in up to 80 % of human cancers, and rapamycin is used clinically to prevent organ-transplant rejection. A striking side-effect: in 15 transplant patients with biopsy-proven Kaposi’s sarcoma, every skin lesion vanished within three months of starting rapamycin. But animal studies show wider benefits: rapamycin slows or reverses age-related decline in cognition, hearing, arteries, tendons, periodontal bone, and even the aging heart—sometimes with only intermittent or transient dosing (e.g., one dose every five days or a short course in middle age). In the Dog Aging Project, 10 weeks of low-dose rapamycin partially reversed age-related heart dysfunction and owners reported livelier dogs.
Human data remain sparse. Autopsy studies show mTOR activity up to 100-fold higher in Alzheimer’s brains, and rapamycin restores memory in Alzheimer mouse models, prompting calls for clinical trials—none yet exist. Small pilot studies of low-dose rapamycin in older adults found no major side-effects (aside from diarrhea in some) but also no immediate cognitive or physical gains. A larger 2018 trial gave hundreds of adults 65+ a six-week course of very low-dose mTOR inhibition: instead of immune suppression they saw immune rejuvenation—better flu-vaccine response and fewer infections over the next year.
Still, rapamycin can cause life-threatening infections at higher doses and remains off-patent, limiting commercial incentive for large trials. Until risks are clearer, self-experimentation is discouraged—though a clinic now caters to people doing just that. Advocates note anti-aging doses are far lower than oncology or transplant regimens and may actually revitalize immunity, especially with transient or intermittent use. But we won’t know without rigorous studies.
Fortunately, there are ways to tamp down mTOR without drugs—most notably through dietary strategies Dr Greger covers elsewhere (fasting-mimicking diets, protein moderation, plant-forward eating, etc.).
We’d love to hear your own evidence-based-nutrition success stories—submit them at Share Your Story; we might share them to inspire others.
If you want the graphs, charts, and sources mentioned here, visit the Nutrition Facts Podcast landing page. My latest book, How Not to Age, is out now (check your local library!), and there’s also a mini-book on Ozempic. All my proceeds go to charity. NutritionFacts.org is a nonprofit, ad-free public service—no sponsorships, no products, just science in bite-sized videos and articles, offered as a labor of love and a tribute to my grandmother, whose life was saved with evidence-based nutrition.
1 Like
chatGPT summary of transcript:
Summary of the transcript
Dr Michael Greger’s podcast episode introduces rapamycin—a compound first isolated from soil bacteria on Easter Island—and explains why scientists consider it one of the most promising anti-aging interventions yet discovered.
-
The problem with current “longevity” medicine
Modern treatments typically extend life by prolonging the morbidity phase—we live longer but spend more years sick. A better goal is to slow the underlying aging process so deterioration sets in later. -
mTOR: the growth engine that becomes an aging accelerator
- Rapamycin blocks an enzyme called mTOR (“mechanistic target of rapamycin”).
- mTOR drives growth in childhood, but in adulthood its relentless activity promotes cellular wear, suppresses the body’s cleanup program (autophagy), and fuels cancer—an example of antagonistic pleiotropy (genes helpful early in life harm us later).
-
Evidence from animal studies
- In every species tested—worms, flies, mice, even dogs—rapamycin lengthens average and maximal lifespan, sometimes even when started late in life.
- Benefits extend beyond cancer protection: the drug slows or reverses age-related decline in cognition, heart function, hearing, arteries, tendons, and periodontal bone.
- Intermittent or low-dose schedules often suffice; in the Dog Aging Project, ten weeks of low-dose rapamycin partly restored heart performance and made pets “perkier.”
-
What we (don’t) know in humans
- Autopsies show mTOR activity can be up to 100-fold higher in Alzheimer brains; rapamycin rescues memory in mouse Alzheimer models, but no full-scale human trials exist.
- Small pilot studies in older adults found low-dose rapamycin safe (occasional diarrhea) but too short to see functional gains.
- A larger 2018 trial using a very low-dose, six-week course unexpectedly improved immune responses to flu vaccine and cut infections the following year, hinting that brief mTOR inhibition may rejuvenate rather than suppress immunity.
-
Caution and barriers to progress
- At transplant-level doses rapamycin can cause dangerous infections, and because the drug is off-patent, there’s little commercial incentive for expensive longevity trials.
- Self-experimenters do exist (one U.S. clinic now caters to them), but Dr Greger counsels against DIY use until rigorous data clarify the long-term risk–benefit profile.
-
Drug-free ways to dial down mTOR today
- Dietary strategies—intermittent or “fasting-mimicking” regimens, moderate protein intake, and plant-forward diets—naturally temper mTOR activity and may confer longevity benefits without pharmaceutical risks.
-
Closing notes
Dr Greger invites listeners to share personal nutrition success stories, plugs his new book How Not to Age, reminds us all proceeds go to charity, and underscores NutritionFacts.org’s ad-free, evidence-based mission.
In short, rapamycin (and by extension, mTOR inhibition) represents one of the most validated paths to extending healthy lifespan in animal models, but human evidence is still preliminary. While low-dose, intermittent regimens look promising—especially for immune rejuvenation—large, long-term trials are needed, and in the meantime diet remains the safest lever most of us can pull to keep mTOR—and aging—on a tighter leash.
2 Likes
Incidentally it takes me less time to get a transcript and summary normally than watching the video. I think it is useful to post these verbatim whereas otherwise I would post a link to the chatGPT session.
5 Likes